Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Corp. (now Lexaria Bioscience Corp.) on May 10, 2016, regarding events occurring on May 9, 2016. The filing confirms the completion of a corporate name change approved by the company's directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and administrative changes rather than financial performance.
Material Changes
- Name Change: The company's name has officially changed from Lexaria Corp. to Lexaria Bioscience Corp.
- Trading Details: The stock is expected to begin trading under the new name on May 12, 2016, on the Canadian Securities Exchange (CSE) and the OTCQB.
- Identifiers: Stock symbols remain LXX (CSE) and LXRP (OTCQB). The CUSIP (52886N 307) and ISIN (US52886N3070) remain unchanged.
- Share Structure: There is no consolidation of shares, and no change in the quantity of shares issued, outstanding, or authorized.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors. The primary operational impact noted is that shareholders are not required to exchange existing share certificates; electronic holdings will be updated automatically.
Investor Verification Checklist
- Verify the new ticker symbol usage on trading platforms starting May 12, 2016.
- Confirm that existing share certificates remain valid without the need for physical exchange.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the rebranding.
- Check subsequent filings for the first financial report issued under the new corporate name.